Dynamic Fitness Landscapes and Evolutionary Constraint in Prostate Cancer

QUIET BIOLOGY FRAMEWORK | Scientific Support Document

Finley Proudfoot | Quiet Biology Framework | March 2026

A Note on This Paper

This paper is a theoretical synthesis rather than a conventional literature review. It draws on evolutionary biology, cancer ecology, and clinical oncology to build an argument about why oscillating environments constrain tumour adaptation. References are provided selectively at the four points where specific external findings are foundational to the argument, the clonal evolution and metastatic seeding literature, the adaptive lag literature, the adaptive therapy clinical data, and the ecological disturbance framework, and are not provided for the paper's own synthesis and application of those concepts to the quiet biology framework. That synthesis is the contribution of this paper, and it stands or falls on its own coherence.

This paper sits alongside the Chronic Activation vs Oscillation paper in the series. Where that paper argues the oscillation case from the cellular signalling level, why pulsatile signals and chronic signals produce different cellular outcomes, this paper argues the same case from the evolutionary population level: why oscillating environments prevent tumour populations from reaching stable adaptive optima. The two arguments are complementary and mutually reinforcing.

Abstract

Cancer progression is increasingly understood as an evolutionary process occurring within a dynamic ecological environment. Tumour populations adapt to selective pressures imposed by the host microenvironment and by therapeutic interventions. Traditional cancer treatments often apply continuous maximal pressure with the objective of eliminating malignant cells. While this approach can produce rapid short-term responses, it frequently accelerates evolutionary adaptation by creating selective environments in which resistant phenotypes become dominant.

Evolutionary biology provides a framework for understanding why such outcomes occur. Tumour populations evolve within fitness landscapes, theoretical representations of how different phenotypes perform under prevailing environmental conditions. When those conditions remain stable, natural selection drives populations toward optimal adaptive states. When environments fluctuate, however, populations may fail to converge on a stable adaptive peak. In such systems, evolutionary adaptation lags behind environmental change, producing chronically maladapted populations.

This paper explores the implications of dynamic fitness landscapes for prostate cancer management. It argues that oscillating environmental conditions, whether arising from therapeutic cycling, metabolic modulation, or physiological perturbations such as exercise, may constrain tumour adaptation by preventing stable evolutionary optimisation. Within this framework, prostate cancer management can be understood not solely as the elimination of malignant cells but as the governance of evolutionary landscapes in which tumour populations exist.

01Cancer as Evolution in a Fitness Landscape

Evolutionary biology describes adaptation using the concept of a fitness landscape: a theoretical representation of how different phenotypes perform within a given environment. In this landscape, each point corresponds to a specific biological state, and elevation corresponds to reproductive success or evolutionary fitness. Populations tend to evolve toward fitness peaks, phenotypes that maximise survival and reproduction under prevailing environmental conditions. Importantly, these peaks are not intrinsic properties of the organism. They are defined by the environment in which the organism exists.^[1]

In cancer, tumour cells occupy positions within a similar evolutionary landscape. Their fitness is determined by interactions with nutrient availability, oxygen gradients, immune surveillance, stromal regulation, endocrine signalling, and therapeutic intervention. Changes in any of these variables reshape the fitness landscape, altering which tumour phenotypes possess the greatest evolutionary advantage. Within this framework, tumour progression is not simply the result of accumulating mutations. It is the process by which tumour populations move through a changing evolutionary landscape toward phenotypes that best exploit their environment.

This framing connects directly to the metabolic argument developed across the Quiet Biology series. The MDM2 Convergence paper established that chronic AKT activation, driven by insulin excess, simultaneously suppresses p53 and dysregulates AR turnover. In evolutionary terms, this is a stable fitness landscape feature: a persistently elevated insulin environment selects for tumour phenotypes that have adapted to exploit it. Correcting the metabolic field does not merely reduce a molecular signal. It reshapes the fitness landscape in which the tumour population is evolving.

02Therapeutic Pressure and Landscape Reshaping

Conventional oncologic therapy often applies continuous, maximal pressure with the aim of eliminating malignant populations as rapidly as possible. While this approach may produce substantial reductions in tumour burden, it also reshapes the fitness landscape in ways that favour resistant phenotypes. When therapy eliminates sensitive tumour cells, the ecological niches those cells occupied become available. Resistant variants that previously existed as minor populations may now occupy the highest available fitness peaks in the new therapeutic environment. What appears clinically as treatment failure is often the predictable outcome of evolutionary selection.^[2]

This dynamic is well illustrated in androgen deprivation therapy for prostate cancer. Androgen-sensitive tumour cells dominate the initial tumour ecology because they exploit the androgen-rich hormonal environment. When androgen signalling is suppressed pharmacologically, this ecological niche collapses. Cells capable of surviving in low-androgen conditions, through receptor hypersensitivity, ligand independence, or lineage plasticity, gain a strong selective advantage. The tumour that emerges following prolonged suppression is therefore not merely the original tumour returning. It is a new evolutionary community shaped by the selective pressures imposed during treatment.[2a]

The BAT paper in this series documents the clinical consequence of this process and its reversal: by cycling between supraphysiological testosterone and castration, BAT destabilises the adapted CRPC population and restores sensitivity to androgen deprivation. In evolutionary terms, BAT is a landscape-reversal strategy, it removes the stable low-androgen environment that CRPC cells have optimised for and replaces it with a rapidly alternating environment that no phenotype can optimise for simultaneously.

03Adaptive Therapy and Competitive Suppression

Recognition of the evolutionary consequences of continuous therapy has led to the development of adaptive therapy, an approach that modulates treatment intensity in order to preserve ecological competition within tumours. Rather than attempting complete elimination of sensitive tumour cells, adaptive therapy maintains these populations so that they continue to compete with resistant clones for resources and space. By preserving competitive suppression, resistant populations are prevented from expanding unchecked.^[3]

Clinical trials in metastatic prostate cancer have demonstrated that adaptive therapy strategies can extend time to progression while using substantially less total drug exposure than conventional continuous dosing, findings that provide empirical support for the ecological interpretation of tumour evolution.^[4]

Adaptive therapy, however, addresses only one dimension of evolutionary management: population competition. A second dimension arises from the dynamics of the evolutionary landscape itself. Preserving sensitive cell populations to suppress resistant ones is a strategy for managing an existing tumour ecology. Dynamic fitness landscapes offer a complementary strategy: making the landscape itself inhospitable to stable evolutionary optimisation, regardless of which population is currently dominant.

04Dynamic Fitness Landscapes and Adaptive Lag

In classical evolutionary theory, populations evolve toward local fitness peaks when the environment remains stable. When the environment changes slowly, populations can track these changes and remain near the moving optimum. When the environment changes rapidly, however, populations may fail to keep pace. The result is adaptive lag, a state in which organisms remain maladapted because the optimal phenotype shifts faster than evolutionary processes can track it.^[5]

Mathematically, this condition arises when the rate of environmental change exceeds the rate of adaptive genetic or phenotypic adjustment. In such systems, populations continually pursue an adaptive peak that has already moved elsewhere. The evolutionary distance between the current population state and the optimal state remains large, not because the population is failing to evolve, but because the target is moving faster than evolution can follow.^[6]

This principle has important implications for cancer evolution. Tumour populations often adapt efficiently to stable environments, evolving phenotypes optimised for specific metabolic, hormonal, or therapeutic conditions. If those conditions fluctuate continuously, however, tumour populations may never reach a stable evolutionary optimum. Instead, they remain trapped in a state of incomplete adaptation, chronically maladapted, and therefore constrained in their capacity for progressive evolutionary escape.

Prostate cancer's unusually slow evolutionary tempo makes it particularly susceptible to this constraint. Tumour populations that evolve slowly are more vulnerable to environmental fluctuation because their rate of adaptive response is limited relative to the rate at which the landscape can be shifted. This is not an incidental feature. It is the biological condition that makes oscillatory management viable in this disease in ways that would not apply to faster-evolving cancers.

05Oscillating Environments as Evolutionary Constraint

Dynamic fitness landscapes can arise in tumours through multiple mechanisms. Intermittent therapeutic intervention introduces cycles of selective pressure and relief that continuously shift which phenotypes are favoured. Cyclical metabolic environments alter the energetic substrates available to tumour cells, favouring different metabolic configurations at different times. Fluctuating hormonal conditions reshape the endocrine signalling landscape in ways that tumour populations must continuously re-optimise against. Immune activation and suppression cycles alter the immunological niche. Physiological disturbances such as structured exercise introduce transient systemic perturbations across multiple of these axes simultaneously.

In prostate cancer, endocrine signalling represents a particularly powerful environmental variable. Oscillations in androgen signalling, whether through physiological fluctuation or therapeutic cycling, may prevent stable adaptation to either androgen-rich or androgen-depleted states. Bipolar androgen therapy represents an explicit attempt to exploit this phenomenon by rapidly alternating between supraphysiologic androgen exposure and androgen deprivation. More broadly, any strategy that prevents the tumour ecosystem from reaching a stable equilibrium may slow evolutionary optimisation, not by eliminating tumour cells directly, but by keeping the evolutionary landscape in motion.

The four-signal protocol architecture described in the Signal, Stress, and Selection paper, stress, inspection, stabilisation, reconstruction, in temporal sequence, is, in evolutionary terms, a landscape-cycling strategy. Each phase creates a different selective environment. No single phenotype is optimally adapted to all four phases simultaneously. The sequence denies the tumour population the stable environment that stable adaptive optimisation requires.

06Ecological Disturbance and Tumour Stability

Ecological systems outside oncology provide instructive analogies. In natural ecosystems, periodic disturbances, fires, floods, grazing events, prevent the dominance of single species and maintain biodiversity. The intermediate disturbance hypothesis proposes that moderate, periodic disturbance maximises species diversity by preventing competitive exclusion while not destroying populations entirely. Stable environments, by contrast, often allow competitive exclusion, in which one species monopolises available resources.^[7]

Tumour ecosystems may behave similarly. Stable metabolic or hormonal environments allow tumour populations to specialise and optimise for those conditions. Disturbances disrupt this specialisation, forcing populations to adapt repeatedly to changing conditions rather than converging on a single dominant phenotype.

Within this framework, physiological processes such as structured exercise may function as systemic ecological disturbances. Exercise induces transient fluctuations in metabolic substrates, oxygen distribution, immune activity, and endocrine signalling. While these perturbations are well tolerated by healthy tissues with full metabolic flexibility, tumour populations operating near the limits of metabolic adaptation may struggle to respond effectively to repeated environmental shifts. Such disturbances do not eliminate tumours directly. They alter the evolutionary landscape in which tumours evolve, and may impose a meaningful constraint on evolutionary convergence.

07Implications for Prostate Cancer Management

This perspective does not reject conventional oncologic therapies. Rather, it reframes their role within a broader evolutionary logic. Aggressive interventions remain appropriate when disease demonstrates clear biological autonomy or rapid progression, when the evolutionary tempo of the tumour has escaped the range in which landscape management is viable. In indolent or early-stage disease, however, preserving ecological containment while avoiding evolutionary acceleration may represent a more rational management strategy than applying continuous maximal pressure.

The metabolic field correction that the Quiet Biology protocol pursues is, in evolutionary terms, a landscape-level intervention. By reducing chronic insulin excess, restoring mTOR oscillation, improving mitochondrial quality, and modulating the hormonal environment, the protocol alters the fitness landscape across multiple axes simultaneously. It does not target a single phenotypic vulnerability, which would simply select for resistant variants that have lost that vulnerability. It changes the environmental conditions that define which phenotypes are viable at all.

It should be stated explicitly: the evolutionary management framework described here is a mechanistic hypothesis grounded in cancer ecology and evolutionary theory. While supporting evidence exists from adaptive therapy trials and experimental models, prospective clinical validation of oscillatory constraint strategies in prostate cancer remains limited. The rationale for this framework rests on biological plausibility and convergent evidence from multiple fields, and should be understood as such.

Conclusion

Cancer evolution occurs within dynamic ecological landscapes shaped by environmental conditions and therapeutic interventions. Traditional cancer therapies often reshape these landscapes in ways that favour resistant phenotypes, accelerating evolutionary escape despite initial tumour regression. This is not treatment failure in any simple sense, it is the predictable outcome of applying stable selective pressure to an evolving population.

Evolutionary theory suggests an alternative possibility. When environmental conditions fluctuate rapidly, populations may fail to converge on stable adaptive states. This phenomenon of adaptive lag can constrain evolutionary optimisation and maintain tumour populations in chronically maladapted configurations. Applied to prostate cancer, this principle implies that maintaining ecological stability while introducing controlled environmental oscillations may slow tumour adaptation and prolong biological containment.

For patients navigating indolent or slowly evolving disease, this framework suggests that therapeutic success may depend not only on the potency of individual interventions but on how those interventions shape the evolutionary landscapes in which tumours evolve. The aim is not to eliminate tumour populations immediately, but to govern the ecological conditions under which their evolution unfolds, constraining the range of available adaptive solutions, and extending the window of biological stability. This is the evolutionary rationale underlying the Quiet Biology approach.

A stable environment is an invitation to adapt.

An oscillating environment is a constraint.

Keep the landscape moving and the tumour cannot find its footing.

References

1. 01Wright S. The roles of mutation, inbreeding, crossbreeding and selection in evolution. Proceedings of the Sixth International Congress of Genetics. 1932;1:356-366. Origin of the fitness landscape concept. Also: Gavrilets S. Fitness Landscapes and the Origin of Species. Princeton University Press. 2004. The definitive modern treatment of fitness landscape theory and its evolutionary implications.
2. 02Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306-313. doi:10.1038/nature10762. Establishes the evolutionary framework for understanding cancer progression, treatment failure, and resistance as outcomes of clonal selection within dynamic tumour ecosystems.
3. 03Gatenby RA, Brown JS. Integrating evolutionary dynamics into cancer therapy. Nature Reviews Clinical Oncology. 2020;17(11):675-686. doi:10.1038/s41571-020-0411-1. The primary theoretical framework paper for adaptive therapy and evolutionary management of cancer, including the competitive suppression rationale.
4. 04Zhang J, Cunningham JJ, Brown JS, Gatenby RA. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nature Communications. 2017;8(1):1816. doi:10.1038/s41467-017-01968-5. Clinical demonstration of adaptive therapy in metastatic prostate cancer, showing extended time to progression with substantially reduced drug exposure relative to standard continuous dosing.
5. 05Bürger R, Lynch M. Evolution and extinction in a changing environment: a quantitative-genetic analysis. Evolution. 1995;49(1):151-163. doi:10.2307/2410312. Foundational mathematical treatment of adaptive lag, the condition in which the rate of environmental change exceeds the rate of adaptive genetic response, producing chronically maladapted populations.
6. 06Kopp M, Matuszewski S. Rapid evolution of quantitative traits: theoretical perspectives. Evolutionary Applications. 2014;7(1):169-191. doi:10.1111/eva.12127. Mathematical analysis of the conditions under which populations track versus lag behind moving fitness optima, including the rate-dependence of adaptive lag.
7. 07Connell JH. Diversity in tropical rain forests and coral reefs. Science. 1978;199(4335):1302-1310. doi:10.1126/science.199.4335.1302. The original statement of the intermediate disturbance hypothesis, that moderate, periodic disturbance maximises biodiversity by preventing competitive exclusion. Applied here as an ecological analogy for tumour phenotypic diversity under oscillating selective pressure.